Our R&D Approach

Our research mission is simple: innovations that improve the quality of life of people everywhere. That motivation keeps us at the forefront of the Healthcare, Life Science and Electronics industries.

Healthcare R&D

Our research scientists are hard at work on groundbreaking medicines and technologies to treat everything from cancer, multiple sclerosis to infertility. Wherever there is a medical need, our highly experienced research and development team hopes to meet it. Learn more

Life Science R&D

R&D focus: Reimagining new ways to meet the needs of our customers

Innovation is at the core of the value that we deliver to our customers. Our Life Science business is research driven and innovation focused. In 2016, we invested 260 million Euro in R&D which supported our innovation in launching 2,100 products – products designed to meet our customers' most unmet needs – from antibodies to water purification systems.

The ability to innovate is the core of our culture across all three of our businesses; Research Solutions, Process Solutions and Applied Solutions. Learn more

Electronics R&D

R&D focus: Keeping the world’s Electronics on the cutting edge

Our Electronics business is an innovation leader, constantly producing new technologies and new markets for our customers, often through partnerships across industries. We have come up with groundbreaking liquid crystal displays and windows, effect pigments for coatings and color cosmetics and high-tech materials for use in integrated circuits. Learn more

Related News

View All News
  1. Press Releases

    Valérie Gabelica Receives 2022 Heinrich Emanuel Merck Award for Analytical ...

    This year’s winner of the Heinrich Emanuel Merck Award for Analytical Science obtained a PhD in Chemical Sciences in 2002 at the University of Liège, Belgium.

    2022/04/20

  2. Press Releases

    European Commission Approves TEPMETKO® (tepotinib) for Patients ...

    Merck KGaA, Darmstadt, Germany today announced today announced that the European Commission (EC) has approved once-daily oral TEPMETKO® (tepotinib) as monotherapy for the treatment of adult patients with ...

    2022/02/18

  3. Press Releases

    Merck KGaA, Darmstadt, Germany, Announces New Appointments in Global R& ...

    Merck KGaA, Darmstadt, Germany today announced new appointments in Global R&D and Strategy leadership for the Healthcare business sector.

    2022/01/13

Healthcare R&D

Our research scientists are hard at work on groundbreaking medicines and technologies to treat everything from cancer, multiple sclerosis and infertility to colds and pains. Wherever there is a medical need, our highly experienced research and development team hopes to meet it. Learn more